Ray Akers, the co-founder and executive chairman of Akers Biosciences (LON:AKR, NASDAQ:AKER), calls the US$1mln order from China for its Heparin allergy tests a ‘game changer’ for the group.

viewAkers Biosciences, Inc.
Akers Biosciences chairman says China deal a ‘game changer’
Quick facts: Akers Biosciences, Inc.
Price: 15.52 USD
NASDAQ:AKR
Market: NASDAQ
Market Cap: $1.34 billion
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive

VR Education 's ENGAGE platform builds momentum
Most read
Industry & services
New space ETF on the horizon lifts shares in Virgin Galactic, Maxar and SRAC
6 days, 18 hours ago
Finance
Are mining stocks on a new bull run? One influential investment bank thinks so
6 days, 18 hours ago
Mining
Pembridge Resources announces appointments of new president and interim CFO...
6 days, 23 hours ago